Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03310411 · ClinicalTrials.gov registry record · Phase 1
A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03310411 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 40 participants.
The verdict
NCT03310411, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether taking lasmiditan and sumatriptan together will have any additional effects on heart rate and blood pressure compared to taking lasmiditan and sumatriptan individually. This study will also look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it when these two drugs are taken together. This study will last about 21 days, not including the screening. Participants will spend 16 days/15 nights in the clinical research unit (CRU) followed by follow-up. Screening is required within 28 days prior to the start of the study.
Interventions
- DRUG Lasmiditan
- DRUG Sumatriptan
- DRUG Placebo for Lasmiditan
- DRUG Placebo for Sumatriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-10-17 |
| Est. Completion | 2017-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03310411
The ClinicalTrials.gov registry entry for NCT03310411 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Lasmiditan is the first listed.
NCT03310411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03310411 about?
NCT03310411 is a clinical study titled "A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants". The purpose of this study is to assess whether taking lasmiditan and sumatriptan together will have any additional effects on heart rate and blood pressure compared to taking lasmiditan and sumatriptan individually. This study will also look at the amount of study drug that gets into the blood strea...
What is the current status of trial NCT03310411?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-10-17. Estimated completion is 2017-12-23.
What interventions are being tested in trial NCT03310411?
The interventions under investigation include: Lasmiditan (DRUG), Sumatriptan (DRUG), Placebo for Lasmiditan (DRUG), Placebo for Sumatriptan (DRUG).
Who is sponsoring clinical trial NCT03310411?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.